{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:17:54Z","timestamp":1788542274244,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"DOI":"10.1007\/s11764-026-02109-y","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:47:10Z","timestamp":1788540430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and ENRICh among cancer survivors on targeted oral anticancer medications (TOAMs)"],"prefix":"10.1007","author":[{"given":"Lisa M.","family":"Lowenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria P.","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik P.","family":"Bergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taahir K.","family":"Busaidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eden R.","family":"Brauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Ganz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Chen Tina","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"2109_CR1","first-page":"153","volume":"68","author":"PM Carrera","year":"2018","unstructured":"Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68:153\u201365.","journal-title":"CA Cancer J Clin"},{"key":"2109_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw205","author":"CK Altice","year":"2017","unstructured":"Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst. 2017. https:\/\/doi.org\/10.1093\/jnci\/djw205.","journal-title":"J Natl Cancer Inst"},{"key":"2109_CR3","unstructured":"Zafar SY, Abernethy AP: Financial toxicity, Part I: a new name for a growing problem. Oncology (Williston Park) 27:80\u20131, 149, 2013"},{"key":"2109_CR4","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/annonc\/mdz140","volume":"30","author":"J Witte","year":"2019","unstructured":"Witte J, Mehlis K, Surmann B, et al. Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications. Ann Oncol. 2019;30:1061\u201370.","journal-title":"Ann Oncol"},{"key":"2109_CR5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1377\/hlthaff.2015.1145","volume":"35","author":"CS Bennette","year":"2016","unstructured":"Bennette CS, Richards C, Sullivan SD, Ramsey SD. Steady increase in prices for oral anticancer drugs after market launch suggests a lack of competitive pressure. Health Aff (Millwood). 2016;35:805\u201312.","journal-title":"Health Aff (Millwood)"},{"key":"2109_CR6","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1001\/jamaoncol.2016.0648","volume":"2","author":"SB Dusetzina","year":"2000","unstructured":"Dusetzina SB. Drug pricing trends for orally administered anticancer medications reimbursed by commercial health plans, 2000\u20132014. JAMA Oncol. 2000;2:960\u20131.","journal-title":"JAMA Oncol"},{"key":"2109_CR7","doi-asserted-by":"publisher","first-page":"e1739","DOI":"10.1200\/OP.22.00171","volume":"18","author":"M Li","year":"2022","unstructured":"Li M, Liao K, Pan IW, Shih YT. Growing financial burden from high-cost targeted oral anticancer medicines among Medicare beneficiaries with cancer. JCO Oncol Pract. 2022;18:e1739-49.","journal-title":"JCO Oncol Pract"},{"key":"2109_CR8","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2014.58.2320","volume":"33","author":"YC Shih","year":"2015","unstructured":"Shih YC, Smieliauskas F, Geynisman DM, et al. Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. J Clin Oncol. 2015;33:2190\u20136.","journal-title":"J Clin Oncol"},{"key":"2109_CR9","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1200\/JCO.2017.72.3742","volume":"35","author":"YT Shih","year":"2017","unstructured":"Shih YT, Xu Y, Liu L, Smieliauskas F. Rising prices of targeted oral anticancer medications and associated financial burden on Medicare beneficiaries. J Clin Oncol. 2017;35:2482\u20139.","journal-title":"J Clin Oncol"},{"key":"2109_CR10","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1200\/JCO.2017.72.3742","volume":"35","author":"Y-CT Shih","year":"2017","unstructured":"Shih Y-CT, Xu Y, Liu L, Smieliauskas F. Rising prices of targeted oral anticancer medications and associated financial burden on Medicare beneficiaries. J Clin Oncol. 2017;35:2482\u20139.","journal-title":"J Clin Oncol"},{"key":"2109_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00520-024-08601-4","volume":"32","author":"LB Thomy","year":"2024","unstructured":"Thomy LB, Crichton M, Jones L, et al. Measures of financial toxicity in cancer survivors: a systematic review. Support Care Cancer. 2024;32:403.","journal-title":"Support Care Cancer"},{"key":"2109_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2023.1188783","volume":"14","author":"JJ Shi","year":"2023","unstructured":"Shi JJ, McGinnis GJ, Peterson SK, et al. Pilot study of a Spanish language measure of financial toxicity in underserved Hispanic cancer patients with low English proficiency. Front Psychol. 2023;14.","journal-title":"Front Psychol"},{"key":"2109_CR13","first-page":"2021","volume":"10\u201314","author":"GL Smith","year":"2021","unstructured":"Smith GL, Mendoza TR, Lowenstein LM, Shih YT. Financial Hardship in Survivorship Care Delivery. J Natl Cancer Inst Monogr. 2021;10\u201314:2021.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2109_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1200\/JCO.2019.37.27_suppl.153","volume":"37","author":"GL Smith","year":"2019","unstructured":"Smith GL, Volk RJ, Lowenstein LM, et al. ENRICH: validating a multidimensional patient-reported financial toxicity measure. J Clin Oncol. 2019;37:153\u2013153.","journal-title":"J Clin Oncol"},{"key":"2109_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272804","volume":"17","author":"C Xu","year":"2022","unstructured":"Xu C, Smith GL, Chen YS, et al. Short-form adaptive measure of financial toxicity from the Economic Strain and Resilience in Cancer (ENRICh) study: derivation using modern psychometric techniques. PLoS ONE. 2022;17.","journal-title":"PLoS ONE"},{"key":"2109_CR16","doi-asserted-by":"publisher","first-page":"e22150","DOI":"10.1200\/JCO.2018.36.15_suppl.e22150","volume":"36","author":"GL Smith","year":"2018","unstructured":"Smith GL, Lowenstein LM, Peterson SK, et al. Financial toxicity of cancer care: defining pathways of decline vs resilience. J Clin Oncol. 2018;36:e22150.","journal-title":"J Clin Oncol"},{"key":"2109_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-25530-x","volume":"25","author":"M Su","year":"2025","unstructured":"Su M, Cong H, Nie H, et al. Cross-cultural adaptation and validation of the ENRICh scale for Chinese infertile patients: a methodological and cross-sectional study. BMC Public Health. 2025;25.","journal-title":"BMC Public Health"},{"key":"2109_CR18","volume-title":"Designing and conducting mixed methods research","author":"JW Creswell","year":"2017","unstructured":"Creswell JW, Clark VLP. Designing and conducting mixed methods research. Sage publications; 2017."},{"key":"2109_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18:59\u201382.","journal-title":"Field Methods"},{"key":"2109_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232076","volume":"15","author":"G Guest","year":"2020","unstructured":"Guest G, Namey E, Chen M. A simple method to assess and report thematic saturation in qualitative research. PLoS ONE. 2020;15.","journal-title":"PLoS ONE"},{"key":"2109_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/104973200129118183","volume":"10","author":"JM Morse","year":"2000","unstructured":"Morse JM. Determining sample size. Qual Health Res. 2000;10:3\u20135.","journal-title":"Qual Health Res"},{"key":"2109_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381.","journal-title":"J Biomed Inform"},{"key":"2109_CR23","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1002\/cncr.28814","volume":"120","author":"JA De Souza","year":"2014","unstructured":"De Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient\u2010reported outcome in cancer: the COST measure. Cancer. 2014;120:3245\u201353.","journal-title":"Cancer"},{"key":"2109_CR24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/cncr.30369","volume":"123","author":"JA De Souza","year":"2017","unstructured":"De Souza JA, Yap BJ, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patient\u2010reported outcome: the validation of the COmprehensive score for financial toxicity (COST). Cancer. 2017;123:476\u201384.","journal-title":"Cancer"},{"key":"2109_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-117","volume":"13","author":"NK Gale","year":"2013","unstructured":"Gale NK, Heath G, Cameron E, et al. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13.","journal-title":"BMC Med Res Methodol"},{"key":"2109_CR26","unstructured":"ATLAS.ti: Scientific Software Development GmbH, (ed 23.2.1), ATLAS.ti Mac, 2023, pp Qualitative data analysis software"},{"key":"2109_CR27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1177\/0081175015578740","volume":"45","author":"CM Abramson","year":"2015","unstructured":"Abramson CM, Dohan D. Beyond text: using arrays to represent and analyze ethnographic data. Sociol Methodol. 2015;45:272\u2013319.","journal-title":"Sociol Methodol"},{"key":"2109_CR28","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1002\/cncr.35367","volume":"130","author":"A Rashidi","year":"2024","unstructured":"Rashidi A, Jung J, Kao R, et al. Interventions to mitigate cancer-related medical financial hardship: a systematic review and meta-analysis. Cancer. 2024;130:3198\u2013209.","journal-title":"Cancer"},{"key":"2109_CR29","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1007\/s11606-021-07258-7","volume":"37","author":"M Wambua","year":"2022","unstructured":"Wambua M, Vang M, Audi C, et al. Lessons learned: recruiting research participants from an underrepresented patient population at a safety net hospital. J Gen Intern Med. 2022;37:922\u20137.","journal-title":"J Gen Intern Med"},{"key":"2109_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000036.pub2","author":"NJ Preston","year":"2016","unstructured":"Preston NJ, Farquhar MC, Walshe CE, et al. Strategies designed to help healthcare professionals to recruit participants to research studies. Cochrane Database Syst Rev. 2016. https:\/\/doi.org\/10.1002\/14651858.MR000036.pub2.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-026-02109-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-026-02109-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-026-02109-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:47:11Z","timestamp":1788540431000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11764-026-02109-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":30,"alternative-id":["2109"],"URL":"https:\/\/doi.org\/10.1007\/s11764-026-02109-y","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I\u2009=\u2009immediate family member, Inst\u2009=\u2009my institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO\u2019s conflict of interest policy, please refer to\u00a0\n                      \n                      \u00a0or\u00a0ascopubs.org\/jco\/authors\/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Lisa M. LowensteinHonoraria:\u00a0NoneConsulting or advisory role: NoneSpeakers\u2019 bureau: NoneTravel, accommodations, expenses: NoneResearch funding:\u00a0AstraZeneca, Blue Cross and Blue Shield of TexasOther relationship: NoneMaria P. BernalHonoraria: NoneConsulting or advisory role: NoneSpeaker\u2019s bureau: NoneTravel, accommodations, expenses: NoneResearch funding: NoneOther relationship: NoneErik BergrenHonoraria: NoneConsulting or advisory role: Research Assistant for Capital Policy Analytics under Ike Brannon (ike@capitalpolicyanalytics.com). This is a for-profit economic consulting firmSpeaker\u2019s bureau: NoneTravel, accommodations, expenses: NoneResearch funding:\u00a0NoneOther relationship:\u00a0NoneTaahir BusaidyHonoraria: NoneConsulting or advisory role: NoneSpeaker\u2019s bureau: NoneTravel, accommodations, expenses: NoneResearch funding: NoneOther relationship: NoneEden R. BrauerHonoraria:\u00a0NoneConsulting or advisory role: NoneSpeakers\u2019 bureau: NoneTravel, accommodations, expenses: NoneResearch funding:\u00a0NoneOther relationship: NonePatricia A. GanzHonoraria:\u00a0NoneConsulting or advisory role: Astellas DSMB and consultant; InformedDNA medical advisory boardSpeakers\u2019 bureau: NoneTravel, accommodations, expenses: NoneResearch funding:\u00a0NoneOther relationship: Section editor UpToDate with royalty paymentsGrace Smith, MDHonoraria:\u00a0NoneConsulting or advisory role: NoneSpeakers\u2019 bureau: NoneTravel, accommodations, expenses: NoneResearch funding:\u00a0NoneOther relationship: NoneYa-Chen Tina ShihHonoraria: NoneConsulting or advisory role: Served on Sanofi\u2019s OncoCollective Advisory Board, 2023\u20132024Speakers\u2019 bureau:\u00a0NoneTravel, accommodations, expenses: NoneResearch funding: Blue Cross and Blue Shield of TexasOther relationship:\u00a0No other potential conflicts of interest were reported.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}